sintilimab + gemcitabine + docetaxel

sintilimab + gemcitabine + docetaxel is an investigational combination regimen consisting of the anti-PD-1 monoclonal antibody sintilimab and the chemotherapy agents gemcitabine and docetaxel (often referred to as the GT regimen). Sintilimab is a fully human IgG4 monoclonal antibody that targets programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1 and PD-L2 to restore T-cell-mediated anti-tumor immune responses. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while docetaxel is a taxane that promotes microtubule assembly and inhibits disassembly, leading to cell cycle arrest and apoptosis. This combination is being evaluated in clinical trials, such as a Phase II study in China (ChiCTR2500095527), as a first-line or later-line therapy for patients with advanced epithelioid sarcoma, leveraging the synergistic effects of immune checkpoint inhibition and cytotoxic chemotherapy.

Other names

sintilimab + GTsintilimab + GT regimensintilimab combined with the GT regimensintilimab plus gemcitabine and docetaxel